Talaris Therapeutics, Inc. (TALS)
|Net Income (ttm)||-22.71M|
|Trading Day||May 14|
|Day's Range||13.68 - 14.48|
|52-Week Range||12.70 - 17.50|
BOSTON and LOUISVILLE, Ky. , May 11, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform t...
BOSTON and LOUISVILLE, Ky., May 06, 2021 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc., a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of c...
Talaris Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
Talaris Therapeutics is a late-clinical stage, cell therapy company developing an innovative method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that we believe has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe non-malignant blood, immune and metabolic disorders. In the organ transplant setting, which is our initial focus, we believe our proprietary therapeutic approach, which we call Facilitated Allo-HSCT Therapy, could prevent organ re... [Read more...]
|IPO Date |
May 7, 2021
|Stock Exchange |
|Ticker Symbol |